Pompano Beach, Fla., April 30, 2015 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc. (DSKX), "DS Healthcare" or "the Company" a leading developer of personal care products, today announced that it has regained compliance with the listing requirements of the NASDAQ Capital Market.
As previously reported, on December 16, 2014, NASDAQ notified the Company that its common stock was not in listing compliance as it failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by NASDAQ's listing rules. On April 29, 2015, the Company received a notice from the NASDAQ indicating that since the closing bid price of the Company's common stock had been at $1.00 per share or greater for the last 10 consecutive business days, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.
About DS Healthcare Group
DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, salons and pharmacies. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group's flagship brand, visit www.dslaboratories.com
Forward-looking statements
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies, and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.